Neogenomics, Inc. (NEO)

$19.0701

+0.07

(+0.37%)▲

Market is closed - opens 8 PM, 05 Dec 2023

Insights on Neogenomics, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 137.22M → 151.95M (in $), with an average increase of 5.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -30.79M → -18.51M (in $), with an average increase of 29.0% per quarter

  • Vs IQV

    In the last 3 years, Iqvia Holdings Inc. has given 5.6% return, outperforming this stock by 66.0%

Performance

  • $18.78
    $19.41
    $19.07
    downward going graph

    1.52%

    Downside

    Day's Volatility :3.25%

    Upside

    1.75%

    downward going graph
  • $8.70
    $20.54
    $19.07
    downward going graph

    54.38%

    Downside

    52 Weeks Volatility :57.64%

    Upside

    7.16%

    downward going graph

Returns

PeriodNeogenomics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
33.9%
-1.3%
0.0%
6 Months
14.53%
1.2%
0.0%
1 Year
61.02%
-5.7%
-6.5%
3 Years
-60.42%
17.1%
-6.5%

Highlights

Market Capitalization
2.4B
Book Value
$7.45
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.77
PEG Ratio
3.02
Wall Street Target Price
21.0
Profit Margin
-16.76%
Operating Margin TTM
-14.52%
Return On Assets TTM
-4.02%
Return On Equity TTM
-9.83%
Revenue TTM
574.8M
Revenue Per Share TTM
4.59
Quarterly Revenue Growth YOY
18.0%
Gross Profit TTM
187.9M
EBITDA
-38.1M
Diluted Eps TTM
-0.77
Quarterly Earnings Growth YOY
1.31
EPS Estimate Current Year
-0.18
EPS Estimate Next Year
-0.08
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    76%Buy
    23%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Neogenomics, Inc.(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
4
4
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 10.12%

Current $19.07
Target $21.00

Company Financials

FY17Y/Y Change
Revenue
258.6M
↑ 5.95%
Net Income
-846.0K
↓ 85.22%
Net Profit Margin
-0.33%
↑ 2.01%
FY18Y/Y Change
Revenue
276.7M
↑ 7.01%
Net Income
2.6M
↓ 412.06%
Net Profit Margin
0.95%
↑ 1.28%
FY19Y/Y Change
Revenue
408.8M
↑ 47.73%
Net Income
8.0M
↑ 203.26%
Net Profit Margin
1.96%
↑ 1.01%
FY20Y/Y Change
Revenue
444.4M
↑ 8.71%
Net Income
4.2M
↓ 47.89%
Net Profit Margin
0.94%
↓ 1.02%
FY21Y/Y Change
Revenue
484.3M
↑ 8.97%
Net Income
-8.3M
↓ 300.07%
Net Profit Margin
-1.72%
↓ 2.66%
FY22Y/Y Change
Revenue
509.7M
↑ 5.24%
Net Income
-144.3M
↑ 1628.17%
Net Profit Margin
-28.3%
↓ 26.58%
Q2 FY22Q/Q Change
Revenue
125.1M
↑ 6.74%
Net Income
-35.3M
↓ 28.55%
Net Profit Margin
-28.23%
↑ 13.94%
Q3 FY22Q/Q Change
Revenue
128.8M
↑ 2.97%
Net Income
-36.9M
↑ 4.39%
Net Profit Margin
-28.62%
↓ 0.39%
Q4 FY22Q/Q Change
Revenue
138.7M
↑ 7.71%
Net Income
-22.7M
↓ 38.44%
Net Profit Margin
-16.36%
↑ 12.26%
Q1 FY23Q/Q Change
Revenue
137.2M
↓ 1.07%
Net Income
-30.8M
↑ 35.74%
Net Profit Margin
-22.44%
↓ 6.08%
Q2 FY23Q/Q Change
Revenue
146.9M
↑ 7.07%
Net Income
-24.3M
↓ 20.99%
Net Profit Margin
-16.56%
↑ 5.88%
Q3 FY23Q/Q Change
Revenue
152.0M
↑ 3.43%
Net Income
-18.5M
↓ 23.9%
Net Profit Margin
-12.19%
↑ 4.37%
FY17Y/Y Change
Total Assets
343.3M
↑ 1.85%
Total Liabilities
137.8M
↓ 8.45%
FY18Y/Y Change
Total Assets
505.0M
↑ 47.09%
Total Liabilities
184.6M
↑ 33.94%
FY19Y/Y Change
Total Assets
709.5M
↑ 40.49%
Total Liabilities
202.1M
↑ 9.5%
FY20Y/Y Change
Total Assets
988.3M
↑ 39.3%
Total Liabilities
294.0M
↑ 45.49%
FY21Y/Y Change
Total Assets
1.9B
↑ 89.19%
Total Liabilities
761.5M
↑ 158.98%
FY22Y/Y Change
Total Assets
1.7B
↓ 6.94%
Total Liabilities
742.0M
↓ 2.56%
Q2 FY22Q/Q Change
Total Assets
1.8B
↓ 2.05%
Total Liabilities
748.6M
↓ 0.79%
Q3 FY22Q/Q Change
Total Assets
1.8B
↓ 2.04%
Total Liabilities
742.6M
↓ 0.8%
Q4 FY22Q/Q Change
Total Assets
1.7B
↓ 0.89%
Total Liabilities
742.0M
↓ 0.08%
Q1 FY23Q/Q Change
Total Assets
1.7B
↓ 1.77%
Total Liabilities
734.7M
↓ 0.98%
Q2 FY23Q/Q Change
Total Assets
1.7B
↓ 0.82%
Total Liabilities
738.9M
↑ 0.57%
Q3 FY23Q/Q Change
Total Assets
1.7B
↓ 1.0%
Total Liabilities
730.8M
↓ 1.1%
FY17Y/Y Change
Operating Cash Flow
18.0M
↓ 16.02%
Investing Cash Flow
-13.7M
↑ 110.58%
Financing Cash Flow
-4.1M
↓ 84.17%
FY18Y/Y Change
Operating Cash Flow
44.8M
↑ 148.3%
Investing Cash Flow
-139.7M
↑ 920.36%
Financing Cash Flow
92.0M
↓ 2345.64%
FY19Y/Y Change
Operating Cash Flow
23.4M
↓ 47.82%
Investing Cash Flow
-19.6M
↓ 85.95%
Financing Cash Flow
159.5M
↑ 73.41%
FY20Y/Y Change
Operating Cash Flow
1.5M
↓ 93.75%
Investing Cash Flow
-159.4M
↑ 712.23%
Financing Cash Flow
235.6M
↑ 47.74%
FY21Y/Y Change
Operating Cash Flow
-26.7M
↓ 1930.34%
Investing Cash Flow
-632.4M
↑ 296.62%
Financing Cash Flow
725.3M
↑ 207.85%
FY22Y/Y Change
Operating Cash Flow
-66.0M
↑ 146.95%
Investing Cash Flow
517.0K
↓ 100.08%
Financing Cash Flow
11.8M
↓ 98.37%
Q2 FY22Q/Q Change
Operating Cash Flow
-17.0M
↓ 41.47%
Investing Cash Flow
-6.3M
↓ 152.06%
Financing Cash Flow
1.0M
↓ 83.31%
Q3 FY22Q/Q Change
Operating Cash Flow
-16.3M
↓ 4.26%
Investing Cash Flow
-4.2M
↓ 33.09%
Financing Cash Flow
3.0M
↑ 192.68%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.7M
↓ 77.35%
Investing Cash Flow
-1.1M
↓ 74.68%
Financing Cash Flow
1.8M
↓ 39.1%
Q1 FY23Q/Q Change
Operating Cash Flow
-12.7M
↑ 244.42%
Investing Cash Flow
23.7M
↓ 2333.49%
Financing Cash Flow
1.4M
↓ 23.47%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.5M
↓ 87.8%
Investing Cash Flow
14.9M
↓ 37.04%
Financing Cash Flow
64.0K
↓ 95.36%

Technicals Summary

Sell

Neutral

Buy

Neogenomics, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neogenomics, Inc.
Neogenomics, Inc.
29.69%
14.53%
61.02%
-60.42%
20.1%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
14.08%
3.72%
14.28%
5.57%
145.22%
Agilent Technologies Inc.
Agilent Technologies Inc.
19.77%
8.82%
-15.66%
11.85%
76.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
9.03%
-4.33%
-10.96%
4.53%
103.42%
Danaher Corp.
Danaher Corp.
14.3%
-4.14%
-16.6%
-0.42%
110.24%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
9.33%
6.32%
2.35%
27.14%
76.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neogenomics, Inc.
Neogenomics, Inc.
NA
NA
3.02
-0.18
-0.1
-0.04
0.0
7.45
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.79
48.79
7.21
9.84
0.93
0.24
0.01
15.62
Agilent Technologies Inc.
Agilent Technologies Inc.
33.15
33.15
2.36
5.41
0.22
0.08
0.01
20.01
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
32.16
32.16
4.28
21.56
0.13
0.05
0.0
117.32
Danaher Corp.
Danaher Corp.
27.92
27.92
3.24
7.55
0.12
0.05
0.0
70.93
Iqvia Holdings Inc.
Iqvia Holdings Inc.
35.36
35.36
1.48
10.19
0.2
0.05
0.0
31.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neogenomics, Inc.
Neogenomics, Inc.
Buy
$2.4B
20.1%
NA
-16.76%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.7B
145.22%
48.79
22.93%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$37.0B
76.64%
33.15
18.15%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$189.6B
103.42%
32.16
13.68%
Danaher Corp.
Danaher Corp.
Buy
$163.6B
110.24%
27.92
20.01%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$38.5B
76.13%
35.36
7.51%

Institutional Holdings

  • BlackRock Inc

    15.80%

  • Vanguard Group Inc

    11.25%

  • Brown Advisory Holdings Inc

    6.48%

  • HHG PLC

    5.64%

  • T. Rowe Price Investment Management,Inc.

    4.34%

  • State Street Corporation

    3.87%

Corporate Announcements

  • Neogenomics, Inc. Earnings

    Neogenomics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig

Organization
Neogenomics, Inc.
Employees
2100
CEO
Mr. George A. Cardoza
Industry
Health Services

Discover More

FAQs